New hope for advanced cervical cancer: volrustomig trial underway

NCT ID NCT06943833

First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 22 times

Summary

This study tests a drug called volrustomig in 30 women with advanced cervical cancer (stage IIIA to IVA) who have finished standard chemoradiation without their cancer getting worse. The goal is to see if volrustomig can help keep the cancer from returning or spreading. Participants receive the drug and are monitored for side effects and cancer progression over several years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Arkhangelsk, 163045, Russia

  • Research Site

    Krasnoyarsk, 660133, Russia

  • Research Site

    Moscow, 111123, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 115533, Russia

  • Research Site

    Moscow, 117997, Russia

  • Research Site

    Moscow, 125284, Russia

  • Research Site

    Moscow, 125367, Russia

  • Research Site

    Saint Petersburg, 194291, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Ufa, 450054, Russia

  • Research Site

    Yekaterinburg, 620036, Russia

Conditions

Explore the condition pages connected to this study.